FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $40,214,000 | -33.7% | 1,037,256 | 0.0% | 7.85% | +25.1% |
| Q4 2021 | $60,690,000 | -1.3% | 1,037,256 | 0.0% | 6.28% | -16.7% |
| Q3 2021 | $61,478,000 | -32.0% | 1,037,256 | -0.4% | 7.53% | -16.1% |
| Q2 2021 | $90,392,000 | -2.4% | 1,041,507 | -7.3% | 8.98% | +31.9% |
| Q1 2021 | $92,639,000 | -30.2% | 1,123,576 | -23.0% | 6.81% | -5.9% |
| Q4 2020 | $132,714,000 | +42.2% | 1,459,517 | -37.5% | 7.23% | +5.1% |
| Q3 2020 | $93,360,000 | +16.5% | 2,335,750 | 0.0% | 6.88% | -7.8% |
| Q2 2020 | $80,140,000 | +63.5% | 2,335,750 | +5.8% | 7.46% | +33.9% |
| Q1 2020 | $49,023,000 | +9.6% | 2,207,250 | -3.4% | 5.57% | -25.2% |
| Q4 2019 | $44,731,000 | +26.0% | 2,285,714 | 0.0% | 7.46% | +16.2% |
| Q3 2019 | $35,497,000 | – | 2,285,714 | – | 6.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |